secwatch.observer — SEC 8-K summary
======================================

Issuer:     Checkpoint Therapeutics, Inc. (—)
CIK:        0001651407
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001104659-24-010161
Event type: regulatory
Sentiment:  negative
Materiality: 0.50
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Checkpoint Therapeutics fails Nasdaq board independence rule after director resignation
--------------------------------------------------------------------------------

- Scott Boilen resigned from Board effective Jan 31, 2024; company no longer has majority independent directors as required by Nasdaq Rule 5605(b)(1).
- Nasdaq confirmed non-compliance via letter on Feb 2, 2024; no immediate impact on listing or trading of CKPT common stock.
- Company has cure period until earlier of next annual shareholders' meeting or Jan 31, 2025; if annual meeting before July 29, 2024, compliance due July 29, 2024.
- Board intends to regain compliance with Board Independence Rule before cure period expires.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651407/000110465924010161/0001104659-24-010161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651407/000110465924010161/tm245111d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-010161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer